JUNEVITY
LIVE

Serial Number

98117779

Owner

Junevity, Inc.

Attorney

Christina M. Licursi

Filing Date

Aug 4, 2023

Add to watchlist:

No watchlists yet
View on USPTO

JUNEVITY Trademark

Serial Number: 98117779

JUNEVITY is a trademark filed by Junevity, Inc. on August 4, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Junevity, Inc. (3 trademarks)

338 S Fremont Street, St. 217
San Mateo, CA 94401

Entity Type: 03

Trademark Details

Filing Date

August 4, 2023

Registration Date

Not Registered

Published for Opposition

December 3, 2024

Goods & Services

Research and development in the field of pharmaceutical development; medical and scientific research and development in connection with cell aging and restoration; research and development of new products in the pharmaceutical and biotechnology fields; development of new technology for others in the fields of gene therapy, genome writing, and genome engineering; scientific research and development in the field of pharmaceutical preparations for gene therapy; scientific research and development in the field of enzyme preparations for gene and cell therapy; research and development services in the field of genomics; medical and scientific research in the fields of genomics; providing medical and scientific research information in the fields of genomics; medical and scientific research in the field of genetics for the purpose of elevating single cell genome variants in order to identify transcription factors; scientific research and development and scientific research consulting, all in the field of genomics; medical research, namely, compiling data for research purposes in the field of genomics; providing medical research information in the field of genomics in relation to disease treatment and aging; providing on-line non-downloadable software for collecting, analyzing, reporting, and tracking data and information in the field of genomics; platform as a service (PAAS) featuring computer software platforms for collecting, analyzing, reporting, and tracking data and information in the field of genomics; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the field of genomics; providing temporary use of non-downloadable computer software incorporating machine learning (ML) and artificial intelligence (AI) technology for genomic analysis and sequencing for scientific, medical, and research purposes; providing temporary use of non-downloadable computer software incorporating machine learning (ML) and artificial intelligence (AI) technology for medical and scientific research in the field of genomics; providing temporary use of non-downloadable computer software for providing medical and scientific research information in the field of genomics; providing temporary use of non-downloadable computer software for medical and scientific research in connection with detecting variants in cells to treat disease and mitigate aging; providing temporary use of non-downloadable computer software for research, development and consultancy in the field of genomics; providing temporary use of non-downloadable computer software for compiling data for research purposes in the field of genomics; providing temporary use of non-downloadable computer software for providing medical research information in the field of genomics; providing temporary use of non-downloadable computer software for medical testing, diagnosis, and treatment; providing temporary use of non-downloadable computer software for medical analysis and diagnosis in the field of genomics for the purpose of disease treatment; providing temporary use of non-downloadable computer software for medical analysis and diagnosis in the field of genomics; providing temporary use of non-downloadable computer software for medical and scientific research in connection with aging

Pharmaceutical preparations for the treatment and prevention of human diseases and disorders, namely, metabolic disease, liver diseases, diabetes, obesity, muscle wasting and frailty, dementia and neurological diseases, skin diseases, chronic kidney disease, inflammatory diseases, and lung diseases; pharmaceutical preparations for the treatment of physiological diseases; pharmaceutical products for cell therapy to treat human diseases and disorders, as well as aging; cell therapy products, namely, pharmaceutical preparations for cell therapy to treat human aging, diseases, and disorders, namely, metabolic disease, liver diseases, diabetes, obesity, muscle wasting and frailty, dementia and neurological diseases, skin diseases, chronic kidney disease, inflammatory diseases, and lung diseases; pharmaceutical preparations for gene therapy to treat human diseases and disorders; pharmaceutical gene therapy preparations to treat human diseases and disorders; chemical preparations for pharmaceutical or medical purposes, namely, for gene and cell therapy

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 9, 2026 EXRA
SOU EXTENSION 2 GRANTED
Jan 8, 2026 EX2G
SOU EXTENSION 2 FILED
Jan 8, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 8, 2026 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 22, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 22, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 22, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 22, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 22, 2025 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 1 GRANTED
May 27, 2025 EX1G
SOU EXTENSION 1 FILED
May 27, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
May 27, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 14, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 3, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 11, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 14, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 13, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 22, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 22, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 22, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 5, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 3, 2023 NWOS
NEW APPLICATION ENTERED
Aug 8, 2023 NWAP